The only clinically validated genome-wide NIPT, screens all 23 chromosome pairs, reporting aneuploidies, large deletions and duplications greater than 7 Mb in addition to select microdeletions.
Like most NIPTs, MaterniT® GENOME screens for common trisomies (such as 21, 18, and 13) and fetal sex. Like some more comprehensive NIPTs, it also screens for sex chromosome aneuploidies, and analyzes seven clinically significant microdeletion regions.
Unlike any other NIPT to date, MaterniT GENOME also analyzes every chromosome and can provide information about clinically relevant microdeletions and gains or losses of chromosome material ≥ 7 Mb across the genome.
By combining increased sequencing depth with industry-leading expertise, the MaterniT GENOME test offers a breadth of coverage unlike any other noninvasive prenatal test available to date.
MaterniT GENOME is an ideal fit for high-risk pregnancies where a patient may wish to avoid a diagnostic procedure, or where screening for common aneuploidies may not be enough.
This chart shows a summary of the 453 positive results seen by your peers. To view turnaround times, specimen requirements and other clinical details, view MaterniT GENOME in the test menu.
In addition to NIPT, we also offer: serum screening; carrier screening, from comprehensive to single-gene; diagnostic testing that can be used on prenatal and products of conception (POC) samples, as well as pediatric, cord blood or adult samples; and hereditary cancer screening.